| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $50,000 ) |
| | 2025 | 2025 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 000 | 3 | NIH | 4/16/2025 | $50,000 |
| | 2025 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41CA285005 | Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation | 000 | 1 | NIH | 4/18/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $4,280,884 ) |
| | 2024 | 2024 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44HL139187 | Development of dekaparin to replace animal-sourced heparin | 001 | 4 | NIH | 9/17/2024 | $747,280 |
| | 2024 | 2024 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41CA285005 | Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation | 001 | 1 | NIH | 5/8/2024 | $55,000 |
| | 2024 | 2024 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM145004 | Synthesis of the library of heparan sulfate hexasaccharide mimetics | 001 | 2 | NIH | 9/2/2024 | $1,075,154 |
| | 2024 | 2024 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM148100 | Development of anticoagulant sulfated glycans | 002 | 2 | NIH | 9/24/2024 | $147,420 |
| | 2024 | 2024 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM148100 | Development of anticoagulant sulfated glycans | 001 | 2 | NIH | 9/19/2024 | $942,883 |
| | 2024 | 2024 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 001 | 3 | NIH | 7/15/2024 | $1,463,275 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM149008 | Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase | 000 | 1 | NIH | 6/26/2024 | -$73 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM145004 | Synthesis of the library of heparan sulfate hexasaccharide mimetics | 000 | 1 | NIH | 8/27/2024 | -$387 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41DE032276 | Sulfated Carbohydrates for the Treatment of Periodontitis | 000 | 1 | NIH | 1/31/2024 | $0 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41CA285005 | Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation | 000 | 1 | NIH | 1/8/2024 | $0 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41CA285005 | Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation | 002 | 1 | NIH | 5/29/2024 | $0 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 000 | 2 | NIH | 1/5/2024 | $0 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41CA285005 | Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation | 003 | 1 | NIH | 9/4/2024 | -$148,924 |
| | 2024 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM148100 | Development of anticoagulant sulfated glycans | 000 | 1 | NIH | 9/4/2024 | -$202 |
| | 2024 | 2022 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM140693 | Construction of chondroitin sulfate microarray | 000 | 1 | NIH | 6/25/2024 | $0 |
| | 2024 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 000 | 1 | NIH | 2/21/2024 | -$180 |
| | 2024 | 2020 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44HL139187 | Development of dekaparin to replace animal-sourced heparin | 000 | 3 | NIH | 11/21/2023 | -$362 |
|
| Issue Date FY: 2023 ( Subtotal = $3,571,604 ) |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41CA285005 | Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation | 000 | 1 | NIH | 6/27/2023 | $400,000 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM145004 | Synthesis of the library of heparan sulfate hexasaccharide mimetics | 000 | 1 | NIH | 9/20/2023 | $255,001 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R43GM149008 | Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase | 000 | 1 | NIH | 1/24/2023 | $350,000 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM148100 | Development of anticoagulant sulfated glycans | 000 | 1 | NIH | 8/15/2023 | $355,989 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM142304 | Development of analytical methods for glycosaminoglycans from biological sources | 001 | 3 | NIH | 8/18/2023 | $988,771 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 001 | 2 | NIH | 9/7/2023 | $0 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 000 | 2 | NIH | 9/6/2023 | $874,308 |
| | 2023 | 2023 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R41DE032276 | Sulfated Carbohydrates for the Treatment of Periodontitis | 000 | 1 | NIH | 9/1/2023 | $347,537 |
| | 2023 | 2022 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R44GM142304 | Development of analytical methods for glycosaminoglycans from biological sources | 000 | 2 | NIH | 12/14/2022 | $0 |
| | 2023 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM142304 | Quantitative analysis of heparan sulfate using 13C-labeled standards | 000 | 1 | NIH | 7/20/2023 | -$2 |
| | 2023 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM123792 | Developing Heparan Sulfate Glycan Array | 000 | 4 | NIH | 9/28/2023 | $0 |
| | 2023 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM134738 | Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | 000 | 3 | NIH | 9/28/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,319,986 ) |
| | 2022 | 2022 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM142304 | Development of analytical methods for glycosaminoglycans from biological sources | 000 | 2 | NIH | 9/16/2022 | $988,771 |
| | 2022 | 2022 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM140693 | Construction of chondroitin sulfate microarray | 000 | 1 | NIH | 4/26/2022 | $331,634 |
| | 2022 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM142304 | Quantitative analysis of heparan sulfate using 13C-labeled standards | 000 | 1 | NIH | 11/9/2021 | $0 |
| | 2022 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM142304 | Quantitative analysis of heparan sulfate using 13C-labeled standards | 001 | 1 | NIH | 9/8/2022 | $0 |
| | 2022 | 2020 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R42GM128484 | Reactor for Insect Cell Culture | 000 | 3 | NIH | 7/11/2022 | -$1,034 |
| | 2022 | 2019 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R44GM134738 | Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | 000 | 1 | NIH | 6/29/2022 | -$1,871 |
| | 2022 | 2018 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R41GM123792 | Developing Heparan Sulfate Glycan Array | 001 | 2 | NIH | 6/29/2022 | -$789 |
| | 2022 | 2018 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R42GM128484 | Reactor for Insect Cell Culture | 001 | 1 | NIH | 9/26/2022 | $1,903 |
| | 2022 | 2017 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R41GM123792 | Developing Heparan Sulfate Glycan Array | 000 | 1 | NIH | 6/29/2022 | $0 |
| | 2022 | 2017 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST | RALEIGH | NC | 27606 | WAKE | USA | R41HL139187 | Development of a New Carbohydrate-based Anticoagulant Drug | 000 | 1 | NIH | 9/26/2022 | $1,372 |
|
| Issue Date FY: 2021 ( Subtotal = $2,972,324 ) (Continued on the next page) |
| | 2021 | 2021 | GLYCAN THERAPEUTICS LLC | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM123792 | Developing Heparan Sulfate Glycan Array | 000 | 4 | NIH | 5/10/2021 | $968,047 |
| | 2021 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM142304 | Quantitative analysis of heparan sulfate using 13C-labeled standards | 000 | 1 | NIH | 9/14/2021 | $300,000 |
| | 2021 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R43GM144019 | Development of heparan sulfate-based therapeutics to treat inflammatory diseases | 000 | 1 | NIH | 9/14/2021 | $231,139 |
| | 2021 | 2021 | GLYCAN THERAPEUTICS CORPORATION | 617 HUTTON ST STE 101 | RALEIGH | NC | 27606-6330 | WAKE | USA | R44GM134738 | Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating Glycosaminoglycans | 003 | 3 | NIH | 9/2/2021 | $272,811 |
|
